| __timestamp | BioMarin Pharmaceutical Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 461543000 | 2854000000 |
| Thursday, January 1, 2015 | 634806000 | 3014000000 |
| Friday, January 1, 2016 | 661905000 | 5098000000 |
| Sunday, January 1, 2017 | 610753000 | 3734000000 |
| Monday, January 1, 2018 | 696328000 | 5018000000 |
| Tuesday, January 1, 2019 | 715007000 | 9106000000 |
| Wednesday, January 1, 2020 | 628116000 | 5039000000 |
| Friday, January 1, 2021 | 628793000 | 5363000000 |
| Saturday, January 1, 2022 | 649606000 | 4977000000 |
| Sunday, January 1, 2023 | 746773000 | 6923000000 |
| Monday, January 1, 2024 | 747184000 | 5907000000 |
In pursuit of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Gilead Sciences, Inc. and BioMarin Pharmaceutical Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Gilead Sciences consistently outpaced BioMarin, with R&D expenses peaking at nearly 9.1 billion in 2019, a staggering 220% increase from 2014. In contrast, BioMarin's R&D spending grew steadily, reaching its highest point in 2023 with a 62% increase from 2014. This divergence highlights Gilead's aggressive approach to expanding its research capabilities, while BioMarin maintains a more measured, yet consistent, investment strategy. As the biotech landscape evolves, these strategic choices will likely shape the future trajectories of these industry leaders.
R&D Spending Showdown: Merck & Co., Inc. vs BioMarin Pharmaceutical Inc.
R&D Spending Showdown: AstraZeneca PLC vs Gilead Sciences, Inc.
R&D Spending Showdown: Gilead Sciences, Inc. vs Zoetis Inc.
R&D Spending Showdown: Gilead Sciences, Inc. vs Exelixis, Inc.
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Pharming Group N.V.
Research and Development Expenses Breakdown: Gilead Sciences, Inc. vs Lantheus Holdings, Inc.
Genmab A/S vs BioMarin Pharmaceutical Inc.: Strategic Focus on R&D Spending
Research and Development Investment: BioMarin Pharmaceutical Inc. vs Sarepta Therapeutics, Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Grifols, S.A.
BioMarin Pharmaceutical Inc. or Apellis Pharmaceuticals, Inc.: Who Invests More in Innovation?
Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs ImmunityBio, Inc.
BioMarin Pharmaceutical Inc. vs MorphoSys AG: Strategic Focus on R&D Spending